Satellos Bioscience Inc (MSLE)

$11.25 -0.66 (-5.54%)
Market Cap N/A
Revenue (ttm) 0.00
Net Income (ttm) 0.00
EPS (ttm) N/A
PE Ratio N/A
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio N/A
Volume 105,000
Avg Vol 15,576
Day's Range N/A - N/A
Shares Out N/A
Stochastic %K 39%
Beta N/A
Analysts Strong Buy
Price Target N/A

Company Profile

Satellos Bioscience Inc., a clinical-stage drug development company, focuses on restoring natural muscle repair and regeneration in degenerative muscle diseases in Canada, the United States, and Australia. The company uses its proprietary discovery platform MyoReGenX, an automated microscopy system that recapitulates the muscle stem cell environment ex-vivo. It develops SAT-3247, an oral, small molecule drug candidate for the treatment of Duchenne muscular dystrophy disease. The company has a li...

Industry: Biotechnology
Sector: Healthcare
Address:
Royal Bank Plaza, Suite 2800 South Tower 200 Bay Street, Toronto, Canada
SuperGreenToday
SuperGreenToday May. 5 at 4:54 PM
$MSLE
0 · Reply
nnnuuu
nnnuuu Apr. 30 at 5:01 PM
$MSLE fly my little shitco penny stock DMD company, fly!
1 · Reply
PennyScam
PennyScam Apr. 29 at 1:24 PM
$MSLE That’s good for ICO Therapeutics holders. Awesome. Crazy K
0 · Reply
nnnuuu
nnnuuu Apr. 28 at 8:04 PM
$MSLE $23
0 · Reply
Weightgainclyde
Weightgainclyde Apr. 28 at 3:31 PM
$MSLE this is the quietest board on the planet
1 · Reply
PennyScam
PennyScam Apr. 18 at 8:06 PM
$MSLE Have you looked at the value of your wholly owned ICO subsidiary? Great value here. Crazy K
1 · Reply
Florestan
Florestan Apr. 17 at 2:16 AM
$MSLE ;)
0 · Reply
spaceodyssey2001
spaceodyssey2001 Apr. 16 at 7:16 PM
$MSLE So whether it’s updated TRAILHEAD data in a few months or top-line BASECAMP data before year-end, we feel investors will return to Satellos, and the stock will rebound.
1 · Reply
WBinthehouse
WBinthehouse Apr. 16 at 4:29 PM
$MSLE up 9% on 35k shares. lol
0 · Reply
WBinthehouse
WBinthehouse Apr. 13 at 5:16 PM
$MSLE up 10% on 76k shares. Anemic. Can’t even get out if need be lol.
1 · Reply
Latest News on MSLE
Satellos initiated with a Buy at Guggenheim

2026-04-28T11:00:43.000Z - 15 days ago

Satellos initiated with a Buy at Guggenheim

Satellos initiated with an Outperform at Leerink

2026-04-06T10:41:27.000Z - 5 weeks ago

Satellos initiated with an Outperform at Leerink

Satellos has ‘catalyst-rich; 2026, says H.C. Wainwright

2026-03-30T10:21:50.000Z - 6 weeks ago

Satellos has ‘catalyst-rich; 2026, says H.C. Wainwright

Cantor starts Satellos with an Overweight on DMD therapy potential

2026-03-11T12:00:38.000Z - 2 months ago

Cantor starts Satellos with an Overweight on DMD therapy potential

Satellos initiated with an Overweight at Cantor Fitzgerald

2026-03-11T10:31:41.000Z - 2 months ago

Satellos initiated with an Overweight at Cantor Fitzgerald

Satellos Bioscience Inc. Common Stock trading resumes

2026-03-10T14:10:13.000Z - 2 months ago

Satellos Bioscience Inc. Common Stock trading resumes

Satellos Bioscience Inc. Common Stock trading halted, volatility trading pause

2026-03-10T14:05:15.000Z - 2 months ago

Satellos Bioscience Inc. Common Stock trading halted, volatility trading pause

Satellos presents interim SAT-3247 data at MDA Conference

2026-03-10T11:22:01.000Z - 2 months ago

Satellos presents interim SAT-3247 data at MDA Conference

Satellos price target raised to $40 from $5 at Oppenheimer

2026-02-10T13:12:15.000Z - 3 months ago

Satellos price target raised to $40 from $5 at Oppenheimer

Satellos Announces Pricing of US$50 Million Public Offering in Canada and the United States

Feb 6, 2026, 8:30 AM EST - 3 months ago

Satellos Announces Pricing of US$50 Million Public Offering in Canada and the United States

Satellos Bioscience IPO Registration Document (F-10)

Feb 5, 2026, 4:09 PM EST - 3 months ago

Satellos Bioscience IPO Registration Document (F-10)

SuperGreenToday
SuperGreenToday May. 5 at 4:54 PM
$MSLE
0 · Reply
nnnuuu
nnnuuu Apr. 30 at 5:01 PM
$MSLE fly my little shitco penny stock DMD company, fly!
1 · Reply
PennyScam
PennyScam Apr. 29 at 1:24 PM
$MSLE That’s good for ICO Therapeutics holders. Awesome. Crazy K
0 · Reply
nnnuuu
nnnuuu Apr. 28 at 8:04 PM
$MSLE $23
0 · Reply
Weightgainclyde
Weightgainclyde Apr. 28 at 3:31 PM
$MSLE this is the quietest board on the planet
1 · Reply
PennyScam
PennyScam Apr. 18 at 8:06 PM
$MSLE Have you looked at the value of your wholly owned ICO subsidiary? Great value here. Crazy K
1 · Reply
Florestan
Florestan Apr. 17 at 2:16 AM
$MSLE ;)
0 · Reply
spaceodyssey2001
spaceodyssey2001 Apr. 16 at 7:16 PM
$MSLE So whether it’s updated TRAILHEAD data in a few months or top-line BASECAMP data before year-end, we feel investors will return to Satellos, and the stock will rebound.
1 · Reply
WBinthehouse
WBinthehouse Apr. 16 at 4:29 PM
$MSLE up 9% on 35k shares. lol
0 · Reply
WBinthehouse
WBinthehouse Apr. 13 at 5:16 PM
$MSLE up 10% on 76k shares. Anemic. Can’t even get out if need be lol.
1 · Reply
PennyScam
PennyScam Apr. 13 at 5:13 AM
$MSLE Neither am I. Ck
0 · Reply
WBinthehouse
WBinthehouse Apr. 11 at 5:44 AM
$MSLE got cut in half from high after RS. Not surprised.
0 · Reply
viber7
viber7 Apr. 10 at 3:39 PM
$MSLE risk analysis.
1 · Reply
focafoca99
focafoca99 Apr. 9 at 7:54 PM
$MSLE is previewing its appearance at the Bloom Burton healthcare conference.
0 · Reply
spaceodyssey2001
spaceodyssey2001 Apr. 8 at 11:50 PM
$MSLE Leerink Partners $20 Buy 221% Upside Initiated 04/06/26 H.C. Wainwright $11 Buy 77% Upside Reiterated 03/30/26 Cantor Fitzgerald $52 NPV Buy 732% Upside Initiated 03/11/26 Leede Financial $16 Buy 157% Upside Reiterated 03/11/26 Oppenheimer $40 Buy 542% Upside Reiterated 02/25/26 Canaccord - outdated
0 · Reply
spaceodyssey2001
spaceodyssey2001 Apr. 8 at 11:48 PM
$MSLE
0 · Reply
viber7
viber7 Apr. 8 at 11:44 PM
$MSLE @WBinthehouse This company and CAPR target markets are similar. Marketcap of CAPR is about 15X that of MSLE. Two obvious risks of MSLE. One, will trials be successful? 4 patients so far with double in muscle strength plus favorable proteomic biomarker data suggest good odds of success. Second, several years of trials with need to raise money and lots of dilutions ahead, as you have said. So perhaps MSLE is fairly valued vs CAPR considering the trial risk and dilution needed. Maybe successful trial odds are as high as 50%, and dilution factor of 2 makes MSLE undervalued. If you think success odds are 20% and dilution factor is 3, then MSLE is fairly valued vs CAPR. CAPR is unique in having cardiac benefits which would take many more years to prove for MSLE. Thoughts?
2 · Reply
steven5120
steven5120 Apr. 7 at 1:12 PM
$MSLE $MSCL Yesterday I published a follow up podcast interview with @Satellos Bioscience CEO Frank Gleeson found at https://youtu.be/CpLi7uAs_uM?si=QoqXUcwZf6L8QwKw
0 · Reply
WBinthehouse
WBinthehouse Apr. 7 at 12:41 AM
$MSLE i made a comment first time discovering this ticker that outstanding shares were high and RS was a possibility and I got a ton of flack from pumpers. After the RS I said it’s going back to pennies. More flack. Historical attrition in DMD clinical development is notably high, especially when moving from early to late phases. This is a well documented challenge in the space and one of the key reasons why positive signals don’t always translate to later success. DMD derisking really happens with robust, placebo controlled functional data in the target population. Positive results could drive major re rating. Bottom line still got a long ways to go and PPS will suffer with possibilities of more dilution and RS. There’s a better entry point in the Phase 2 pediatric readout in Q4 2026.
0 · Reply
WBinthehouse
WBinthehouse Mar. 31 at 11:44 PM
$MSLE What’s going on here? Where’s all the pumpers? Told you this is years away lol. All invested here will lose all their money from more RS and dilutions. Sorry not sorry.
2 · Reply
topstockalerts
topstockalerts Mar. 30 at 11:01 AM
Pre Market Top Gainers PT2 $ASTC $ROMA $HOLO $MSLE $LTRN
0 · Reply
topstockalerts
topstockalerts Mar. 24 at 8:22 PM
After Hours Top Gainers $ITOC $NXTT $BRZE $PAVS $MSLE
0 · Reply